ban2401 comparisonone of the questions that had always been bothering me about PMN310 was, "Why does PMN present their dot blot and spr data vs aducanumab but not BAN2401?"
Statements had been made in presentations past about BAN2401 causing ARIA-E, but I was always unsure about its selectivity and binding affinity relative to PMN310.
In the most recent Sachs presentation, I believe Dr. Williams delivered it, there was a verbal statement made while discussing the dot blot data that BAN2401 behaves similarly to aducanumab.
That was a good reassurance to me that we won't get a surprise in the BAN2401 Ph3 trial that it outperforms aducanumab and leaves PMN310 in the dust.
Does anyone know more about BAN2401 or any binding studies, etc vs PMN310?